Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration

NCT02859766 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT02859766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02859766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration
Lead sponsor
Allergan
Phase
Phase 1
Overall status
Completed
Start date
December 7, 2016
Completion date
October 20, 2017
Enrollment
30 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration